English

China Wholesale Large Log Splitter Manufacturers - Dabigatran Etexilate Mesylate – CPF

China Wholesale Large Log Splitter Manufacturers - Dabigatran Etexilate Mesylate – CPF Featured Image
  • China Wholesale Large Log Splitter Manufacturers - Dabigatran Etexilate Mesylate – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We generally believe that one's character decides products' top quality, the details decides products' high-quality ,along with the REALISTIC,EFFICIENT AND INNOVATIVE team spirit for Pregabalin Effects, Sofosbuvir Manufacturer, Ezetimibe, We sincerely welcome customers from both at home and abroad to come to negotiate business with us.
China Wholesale Large Log Splitter Manufacturers - Dabigatran Etexilate Mesylate – CPF Detail:

Description

Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.

Background

Description: IC50 Value: 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1] Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate. in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2]. Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1

Storage

Powder

-20°C

 3 years
 

4°C

 2 years
In solvent

-80°C

 6 months
 

-20°C

 1 month

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase
NCT02170792 Boehringer Ingelheim Healthy February 2001

Phase 1
NCT02170974 Boehringer Ingelheim Healthy July 2004

Phase 1
NCT02170831 Boehringer Ingelheim Healthy May 1999

Phase 1
NCT02170805 Boehringer Ingelheim Healthy April 2001

Phase 1
NCT02170610 Boehringer Ingelheim Healthy March 2002

Phase 1
NCT02170909 Boehringer Ingelheim Healthy December 2004

Phase 1
NCT02171000 Boehringer Ingelheim Healthy April 2005

Phase 1
NCT02170844 Boehringer Ingelheim Healthy June 2004

Phase 1
NCT02170584 Boehringer Ingelheim Healthy January 2001

Phase 1
NCT02170935 Boehringer Ingelheim Venous Thromboembolism April 2002

Phase 2
NCT02170636 Boehringer Ingelheim Healthy January 2002

Phase 1
NCT02170766 Boehringer Ingelheim Healthy October 2000

Phase 1
NCT02171442 Boehringer Ingelheim Healthy April 2002

Phase 1
NCT02170896 Boehringer Ingelheim Healthy October 2001

Phase 1
NCT02173730 Boehringer Ingelheim Healthy November 2002

Phase 1
NCT02170623 Boehringer Ingelheim Healthy February 2002

Phase 1
NCT02170116 Boehringer Ingelheim Healthy November 1998

Phase 1
NCT02170597 Boehringer Ingelheim Healthy August 2003

Phase 1
NCT01225822 Boehringer Ingelheim Venous Thromboembolism November 2002

Phase 2
NCT02170701 Boehringer Ingelheim Venous Thromboembolism October 2000

Phase 2
NCT02170740 Boehringer Ingelheim Healthy November 1999

Phase 1
NCT02170922 Boehringer Ingelheim Healthy July 1999

Phase 1

Chemical structure

Dabigatran Etexilate Mesylate

2018 GMP-2
原料药GMP证书201811（captopril ,thalidomide etc）
GMP-of-PMDA-in-Chanyoo-平成28年08月03日　Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation

Product detail pictures:

China Wholesale Large Log Splitter Manufacturers - Dabigatran Etexilate Mesylate – CPF detail pictures

Related Product Guide:
We continuously execute our spirit of ''Innovation bringing development, Highly-quality ensuring subsistence, Management advertising and marketing gain, Credit history attracting buyers for China Wholesale Large Log Splitter Manufacturers - Dabigatran Etexilate Mesylate – CPF , The product will supply to all over the world, such as: Egypt, Uganda, United Kingdom, As a way to make use of the resource on the expanding information and facts in international trade, we welcome prospects from everywhere on the web and offline. In spite in the top quality products and solutions we supply, effective and satisfying consultation service is supplied by our professional after-sale service group. Solution lists and thorough parameters and any other info weil be sent for you timely for the inquiries. So make sure you get in touch with us by sending us emails or contact us if you have any concerns about our firm. ou can also get our address info from our web site and come to our enterprise. or a field survey of our solutions. We're confident that we have been going to share mutual results and build solid co-operation relations with our companions in this market. We're looking forward to your inquiries.
    • As a veteran of this industry, we can say that the company can be a leader in the industry, select them is right.
    5 Stars By Florence from Greek - 2018.10.31 10:02
    The factory workers have a good team spirit, so we received high quality products fast, in addition, the price is also appropriate, this is a very good and reliable Chinese manufacturers.
    5 Stars By Andy from Birmingham - 2018.04.25 16:46
    Write your message here and send it to us

    Products categories